Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathleen H Goss

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Current Drug Targets|June 16, 2010
A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancerJenifer R Prosperi, Kathleen H Goss
Cancer Cell|March 22, 2014
Janet Davidson Rowley (1925-2013)Kathleen H Goss, Michelle M Le Beau
Toxicologic Pathology|December 8, 2004
Strain-specific of alachlor on murine olfactory mucosal responsesMary Beth Genter, Kathleen H Goss, Joanna Groden
Molecular Carcinogenesis|May 20, 2009
The Ron receptor tyrosine kinase is not required for adenoma formation in Apc(Min/+) miceSara E Meyer, Susan E Waltz, Kathleen H Goss
BMC Cancer|January 11, 2013
APC/β-catenin-rich complexes at membrane protrusions regulate mammary tumor cell migration and mesenchymal morphologyMatthew A Odenwald, Jenifer R Prosperi, Kathleen H Goss
Current Drug Targets|November 9, 2013
Exploiting APC function as a novel cancer therapyAlyssa C Lesko, Kathleen H Goss, Jenifer R Prosperi
Journal of STEM Outreach|June 13, 2022
Adapting Pathway Programs to the Virtual World: Insights from the Chicago EYES on Cancer Response to COVID-19-Related Disruptions to TrainingMegan A Mekinda, Michelle L Domecki, Kathleen H Goss, et al.
Plos One|January 5, 2012
Apc mutation enhances PyMT-induced mammary tumorigenesisJenifer R Prosperi, Andrey I Khramtsov, Galina F Khramtsova, et al.
Plos One|February 7, 2015
β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cellsJinhua Xu, Jenifer R Prosperi, Noura Choudhury, et al.
Carcinogenesis|May 22, 2016
Hsp70 exerts oncogenic activity in the Apc mutant Min mouse modelYun Tao, Jeannette S Messer, Kathleen H Goss, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Current Drug Targets|June 16, 2010
A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancerJenifer R Prosperi, Kathleen H Goss
Cancer Cell|March 22, 2014
Janet Davidson Rowley (1925-2013)Kathleen H Goss, Michelle M Le Beau
Toxicologic Pathology|December 8, 2004
Strain-specific of alachlor on murine olfactory mucosal responsesMary Beth Genter, Kathleen H Goss, Joanna Groden
Molecular Carcinogenesis|May 20, 2009
The Ron receptor tyrosine kinase is not required for adenoma formation in Apc(Min/+) miceSara E Meyer, Susan E Waltz, Kathleen H Goss
BMC Cancer|January 11, 2013
APC/β-catenin-rich complexes at membrane protrusions regulate mammary tumor cell migration and mesenchymal morphologyMatthew A Odenwald, Jenifer R Prosperi, Kathleen H Goss
Current Drug Targets|November 9, 2013
Exploiting APC function as a novel cancer therapyAlyssa C Lesko, Kathleen H Goss, Jenifer R Prosperi
Journal of STEM Outreach|June 13, 2022
Adapting Pathway Programs to the Virtual World: Insights from the Chicago EYES on Cancer Response to COVID-19-Related Disruptions to TrainingMegan A Mekinda, Michelle L Domecki, Kathleen H Goss, et al.
Plos One|January 5, 2012
Apc mutation enhances PyMT-induced mammary tumorigenesisJenifer R Prosperi, Andrey I Khramtsov, Galina F Khramtsova, et al.
Plos One|February 7, 2015
β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cellsJinhua Xu, Jenifer R Prosperi, Noura Choudhury, et al.
Carcinogenesis|May 22, 2016
Hsp70 exerts oncogenic activity in the Apc mutant Min mouse modelYun Tao, Jeannette S Messer, Kathleen H Goss, et al.
Pageof 2